Celsion was the center of a considerable amount of market buzz over the last year as the small biotech pushed a late-stage cancer drug through a Phase III liver cancer study. Its stock price tripled as investors rode a swell of enthusiasm that Celsion could beat the tough odds that face any small-cap company trying to make it all the way through an oncology program.
Celsion ($CLSN) grabbed $5 million in a development deal with China's Zhejiang Hisun Pharmaceutical, which has shown interest in advancing Celsion's ThermoDox product in China, Hong Kong and Macau.
Celsion ($CLSN), a drug-development company based in Columbia, MD, has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency has issued a positive opinion
Celsion, a drug-development company based in Columbia, MD, has been awarded a $200,000 Phase I SBIR grant from the NIH for its low heat-activated liposomes, which the company says enables delivery of
Drug developer Celsion and sufferers of primary liver cancer received some good news from the FDA this week as the Columbia, MD-based company's first drug, ThermoDox, was granted fast-track status.